University of Leicester
Leicester, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
IgA nephropathy
FollowWhat is new in IgA nephropathy research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- ACE Inhibitor or Angiotensin receptor antagonistPhase 3 · NCT07098897
- AtaciceptPhase 3 · NCT07020923 · NCT04716231 · NCT06983028
- AtrasentanPhase 3 · NCT04573478 · NCT04573920 · NCT07850752
- BHV-1400Phase 3 · NCT07054684 · NCT07642050
- BION-1301Phase 3 · NCT05852938
- CorticosteroidPhase 3 · NCT07098897
- Drug: AtrasentanPhase 3 · NCT07498335
- FelzartamabPhase 3 · NCT06935357 · NCT07889362
- HRS-5965Phase 3 · NCT07014826
- HSK39297Phase 3 · NCT07390123
- iptacopanPhase 3 · NCT06994845 · NCT06797518
- JADE101Phase 3 · NCT07541287 · NCT07902817
- LNP023Phase 3 · NCT04557462
- MezagitamabPhase 3 · NCT06963827
- PovetaciceptPhase 3 · NCT06564142 · NCT05732402
- PrednisolonePhase 3 · NCT05510323 · NCT06676579
- Prednisolone plus CyclophosphamidePhase 3 · NCT05510323
- RavulizumabPhase 3 · NCT06291376 · NCT07024563
- SC0062 strength 10mgPhase 3 · NCT06819826
- Sefaxersen (RO7434656)Phase 3 · NCT05797610
- SibeprenlimabPhase 3 · NCT06740526 · NCT07770815
- Sibeprenlimab 400 mgPhase 3 · NCT05248646
- TelitaciceptPhase 3 · NCT07886476 · NCT07522099 · NCT05799287 · NCT07052981
- Telitacicept 160mgPhase 3 · NCT07098897
- ZigakibartPhase 3 · NCT04573478 · NCT06858319 · NCT07850752 · NCT07146906
- ADX-038Phase 2 · NCT07522099
- ADX-038 Dose Level 1Phase 2 · NCT06989359
- ADX-038 Dose Level 2Phase 2 · NCT06989359
- ADX-097Phase 2 · NCT06419205
- ARGX-121Phase 2 · NCT07773727
- Atacicept 150 mgPhase 2 · NCT06674577
- AvacopanPhase 2 · NCT06676579
- CM313Phase 2 · NCT06830395
- CM338Phase 2 · NCT05775042
- EVER001Phase 2 · NCT07614477
- HRS-5965 CapsulesPhase 2 · NCT07582133
- HS-10542 High DosePhase 2 · NCT07474636
- HS-10542 Low DosePhase 2 · NCT07474636
- HSK39297 200mgQDPhase 2 · NCT07616700
- HSK39297 300mgQDPhase 2 · NCT07616700
- Hydroxychloroquine Oral TabletPhase 2 · NCT06350630
- KP104Phase 2 · NCT05517980
- Methylprednisolone (drug)Phase 2 · NCT06676579
- MY008211A tabletsPhase 2 · NCT06687174
- MY008211A tablets matched placeboPhase 2 · NCT06687174
- Mycophenolate Mofetil (MMF)Phase 2 · NCT07785128
- NM8074Phase 2 · NCT06454110
- NTQ5082 capsules 100 mgPhase 2 · NCT06982040
- NTQ5082 capsules 200 mgPhase 2 · NCT06982040
- NTQ5082 capsules 300 mgPhase 2 · NCT06982040
- PrednisolonPhase 2 · NCT07785128
- PrednisonePhase 2 · NCT06676579
- QLS7305 InjectionPhase 2 · NCT07730632
- RG002C0106Phase 2 · NCT07445906 · NCT07305974
- SGB-9768Phase 2 · NCT06786338
- SHR-2173 injectionPhase 2 · NCT07354932
- SLN12140Phase 2 · NCT07553494
- SparsentanPhase 2 · NCT04663204 · NCT05003986
- STL303Phase 2 · NCT07606352
- Matching PlaceboPhase 1/2 · NCT07375758
- MIL116Phase 1/2 · NCT07375758
- PS-002Phase 1/2 · NCT07182227
- SCTC21CPhase 1/2 · NCT06774664
- Budesonide delayed release tabletPhase 1 · NCT07897240
- CLYM116Phase 1 · NCT07248865
- IBI3034Phase 1 · NCT07886476
- UCAR T-cellPhase 1 · NCT07507201 · NCT07305116
- anti-CD19/BCMA CAR NK cells (KN5601)Early phase 1 · NCT06792799
- CD19 CAR-γδ T cellEarly phase 1 · NCT07535138
- CD19-targeted iNKT Cell InjectionEarly phase 1 · NCT07389499
- IM19 chimeric antigen receptor T cell injectionEarly phase 1 · NCT06690359
- QT-219CXEarly phase 1 · NCT07586267
- RD06-05 CART Cell InfusionEarly phase 1 · NCT07674147
- RD06-05 CART Cell InjectionEarly phase 1 · NCT07203404
- SCFA → Placebo (Sequence SP) and Placebo → SCFA (Sequence PS)Early phase 1 · NCT07750249
- YKST02Early phase 1 · NCT07498673
Closest to patients
- Atacicept in Subjects With IgA NephropathyAtacicept in Subjects With IgA NephropathyVseobecna Fakultni Nemocnice V Praze · Prague 2, Czechia + 35 more hospitalsPhase 3Primary completion 2025
- To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA NephropathyTo Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA NephropathyThe First Affiliated hospital of Xuzhou Medical University · Xuzhou, ChinaPhase 3Primary completion 2025
- Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKDEfficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKDAFMMU · Xi'an, ChinaPhase 3Primary completion 2025
Choose one to continue
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Integrated Transcriptomic Analysis and Experimental Validation Identify ATF3 as a Mesangial Cell-Associated Candidate Regulator in IgA Nephropathy.
Integrated Transcriptomic Analysis and Experimental Validation Identify ATF3 as a Mesangial Cell-Associated Candidate Regulator in IgA Nephropathy.
Journal of inflammation research
PubMed · PMID 42979491Publication
Multi-Omics Analysis Uncovers a Link Between Dysregulated Steroid Hormone Biosynthesis and Pediatric IgA Vasculitis Nephritis.
Multi-Omics Analysis Uncovers a Link Between Dysregulated Steroid Hormone Biosynthesis and Pediatric IgA Vasculitis Nephritis.
Frontiers in bioscience (Landmark edition)
PubMed · PMID 42980025Case report
IgA nephropathy in a patient with 17α-hydroxylase/17,20-lyase deficiency caused by the CYP17A1 p. Y329fs mutation: a case report and review.
IgA nephropathy in a patient with 17α-hydroxylase/17,20-lyase deficiency caused by the CYP17A1 p. Y329fs mutation: a case report and review.
BMC pediatrics
PubMed · PMID 42983718
Organisations that can help
Helplines, patient groups and support services for you and your family.
International & European
European Kidney Patients' Federation
Federation of national kidney patient organisations: information materials, webinars, annual summit, youth camp, EU advocacy.
Visit site: European Kidney Patients' FederationEuropean Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
Visit site: EURORDIS – Rare Diseases EuropeIgA Nephropathy Foundation
Patient-run IgAN non-profit (US-based, 'Go Global Network'): education, provider finder, patient registry, app, patient aid, research and clinical trial information.
Visit site: IgA Nephropathy FoundationInternational Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' Organizations
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active IgA nephropathy work.
Peking University First Hospital
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Juntendo University
Tokyo, Japan
Team details appear once the team leader joins.
Is this your team? Claim it
Peking University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Stanford Medicine
Stanford, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Alabama at Birmingham
Birmingham, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Jikei University School of Medicine
Tokyo, Japan
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang Chinese Medical University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Stanford University
Stanford, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
University of British Columbia
Vancouver, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
UNSW Sydney
Sydney, Australia
Team details appear once the team leader joins.
Is this your team? Claim it